External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>In 3Q24, RemeGen achieved robust product sales, with revenue reaching a record high of RMB467mn (+14% QoQ, +35% YoY), driven by product sales of RC18 (~RMB270mn, +43% YoY) and RC48 (~RMB200mn, +25% YoY).</li><li>Total revenue in 9M24 was RMB1,209mn (+57% YoY), representing approximately 73% of our previous FY24 estimate, aligning with our expectations.</li><li>We are reassured that the Company will meet its FY24 sales target of a 50%+ YoY increase, and expect the strong sales momentum to continue in 4Q24 and beyond. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

In 3Q24, RemeGen achieved robust product sales, with revenue reaching a record high of RMB467mn (+14% QoQ, +35% YoY), driven by product sales of RC18 (~RMB270mn, +43% YoY) and RC48 (~RMB200mn, +25% YoY).Total revenue in 9M24 was RMB1,209mn (+57% YoY), representing approximately 73% of our previous FY24 estimate, aligning with our expectations.We are reassured that the Company will meet its FY24 sales target of a 50%+ YoY increase, and expect the strong sales momentum to continue in 4Q24 and beyond. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

RemeGen (9995 HK) - Strong Sales in Q3, with a Narrowed Net Loss

Smartkarma Research Team, Smartkarma

Smartkarma Research

Smartkarma Research Team

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<p>For our next Corporate Webinar, we are glad to welcome RemeGen's Chief Financial Officer, Mr. Tong Shaojing.</p>
<p>In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, <a href="https://www.smartkarma.com/profiles/eric-wen" target="_blank" data-smartkarma-citation="accounts:54017" rel="noopener">Eric Wen</a> . The Corporate Webinar will include a live Q&amp;A session.</p>
<h3>The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.</h3>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div>
<div class="content-highlight">
<h2><a href="https://share.hsforms.com/1H9pFZOB-RF2J00kbvMmxcw2c5gj?zoom_webinar_id=88131022121" target="_blank" rel="noopener">Register for the Webinar here</a></h2>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<h3>About RemeGen</h3>
<p>RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.</p>

For our next Corporate Webinar, we are glad to welcome RemeGen's Chief Financial Officer, Mr. Tong Shaojing.
In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Eric Wen . The Corporate Webinar will include a live Q&amp;A session.
The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.












Register for the Webinar here












About RemeGen
RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

<ul><li>In 2Q24, RemeGen recorded strong product sales, with revenue reaching RMB411mn (+77% YoY), mainly from the product sales of RC18 and RC48, compared to RMB330mn in 1Q24 (+24% QoQ) and RMB254mn in 2Q23 (+62% YoY).</li><li>The total product sales were RMB729mn in 1H24 (+75% YoY), representing approximately 47% of our previous FY24 estimate, largely in line with our expectations.</li><li>We are reassured that the Company is on track to meet its FY24 sales target of 50%+ YoY increase. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

In 2Q24, RemeGen recorded strong product sales, with revenue reaching RMB411mn (+77% YoY), mainly from the product sales of RC18 and RC48, compared to RMB330mn in 1Q24 (+24% QoQ) and RMB254mn in 2Q23 (+62% YoY).The total product sales were RMB729mn in 1H24 (+75% YoY), representing approximately 47% of our previous FY24 estimate, largely in line with our expectations.We are reassured that the Company is on track to meet its FY24 sales target of 50%+ YoY increase. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

RemeGen (9995 HK) - Strong Sales Performance in 2Q

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>One “unique” feature of China's CXOs is that they like investment more than drug R&amp;D business, but the investment-driven model will result in "interest-to-conflict", which actually “crosses the line”.</li>
<li>RemeGen's shares plummet last week. In current situation of investors' lack of confidence/trust in RemeGen, stock price may not have hit bottom yet, so no need to rush to bottom-fish.</li>
<li>For Kelun Bio, if SKB264 fails to deliver good data, valuation would face the risk of pullback. After the lock-up expiry, there could be opportunity to buy at lower price.</li>
</ul>


One “unique” feature of China's CXOs is that they like investment more than drug R&amp;D business, but the investment-driven model will result in "interest-to-conflict", which actually “crosses the line”.
RemeGen's shares plummet last week. In current situation of investors' lack of confidence/trust in RemeGen, stock price may not have hit bottom yet, so no need to rush to bottom-fish.
For Kelun Bio, if SKB264 fails to deliver good data, valuation would face the risk of pullback. After the lock-up expiry, there could be opportunity to buy at lower price.


China Healthcare Weekly (July.14) - CXO's Disputed Business Model, Remegen Shares Plunged, Kelun Bio

<ul><li>RemeGen recorded RMB1.08bn of revenue in FY23, including RMB1.05bn from product sales (+42% YoY), contributed equally by RC18 and RC48.</li><li>In FY23, GP margin (vs product sales) increased to 76.9% (vs 63.4% in FY22).</li><li>Selling expense ratio (vs product sales) increased from 60% in FY22 to 74% in FY23, mainly due to an increase in sales headcount. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

RemeGen recorded RMB1.08bn of revenue in FY23, including RMB1.05bn from product sales (+42% YoY), contributed equally by RC18 and RC48.In FY23, GP margin (vs product sales) increased to 76.9% (vs 63.4% in FY22).Selling expense ratio (vs product sales) increased from 60% in FY22 to 74% in FY23, mainly due to an increase in sales headcount. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

RemeGen (9995 HK) - Awaiting the Fruition of Overseas BD Collaborations

China

RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Remegen (9995 HK)

RemeGen (9995 HK) - Strong Sales in Q3, with a Narrowed Net Loss

In 3Q24, RemeGen achieved robust product sales, with revenue reaching a record high of RMB467mn (+14% QoQ, +35% YoY), driven by product sales of...

CMB International

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

RemeGen (9995 HK) is a leading biotech company committed to the discovery, development, and commercialization of innovative biologic drugs. Learn...

Smartkarma Research

RemeGen (9995 HK) - Strong Sales Performance in 2Q

In 2Q24, RemeGen recorded strong product sales, with revenue reaching RMB411mn (+77% YoY), mainly from the product sales of RC18 and RC48

CMB International

China Healthcare Weekly (July.14) - CXO's Disputed Business Model, Remegen Shares Plunged, Kelun Bio

China CXOs prioritize investment over R&D, leading to potential conflicts of interest. Investors challenged RemeGen due to poor outlook. After...

Xinyao (Criss) Wang

RemeGen (9995 HK) - Awaiting the Fruition of Overseas BD Collaborations

RemeGen recorded RMB1.08bn of revenue in FY23, including RMB1.05bn from product sales (+42% YoY), contributed equally by RC18 and RC48.

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

RemeGen (9995 HK) - Strong Sales in Q3, with a Narrowed Net Loss

In 3Q24, RemeGen achieved robust product sales, with revenue reaching a record high of RMB467mn (+14% QoQ, +35% YoY), driven by product sales of...

CMB International

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

RemeGen (9995 HK) is a leading biotech company committed to the discovery, development, and commercialization of innovative biologic drugs. Learn...

Smartkarma Research

RemeGen (9995 HK) - Strong Sales Performance in 2Q

In 2Q24, RemeGen recorded strong product sales, with revenue reaching RMB411mn (+77% YoY), mainly from the product sales of RC18 and RC48

CMB International

China Healthcare Weekly (July.14) - CXO's Disputed Business Model, Remegen Shares Plunged, Kelun Bio

​China CXOs prioritize investment over R&D, leading to potential conflicts of interest. Investors challenged RemeGen due to poor outlook. After...

Xinyao (Criss) Wang

RemeGen (9995 HK) - Awaiting the Fruition of Overseas BD Collaborations

RemeGen recorded RMB1.08bn of revenue in FY23, including RMB1.05bn from product sales (+42% YoY), contributed equally by RC18 and RC48.

CMB International

China CXOs prioritize investment over R&D, leading to potential conflicts of interest. Investors challenged RemeGen due to poor outlook. After...